1. Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis
- Author
-
Xiaofei Li, Yuexiao Yu, and Liwen Liu
- Subjects
Oncology ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Prospective cohort study ,Retrospective Studies ,Aspirin ,Hepatology ,business.industry ,Liver Neoplasms ,Gastroenterology ,Retrospective cohort study ,medicine.disease ,Confidence interval ,Treatment Outcome ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Relative risk ,Meta-analysis ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Summary Background Aspirin use has been suggested to reduce cancer risk. However, previous studies showed inconsistent results as for the association between aspirin use and mortality in patients with hepatocellular carcinoma (HCC). The aim of the study was to evaluate the influence of aspirin use on clinical outcomes of patients with HCC in a meta-analysis. Materials Studies were obtained via systematic search of PubMed, Cochrane’s Library, and Embase databases. A random-effect model, which incorporated the potential heterogeneity, was used to pool the results. Results Six retrospective cohort studies including 18,855 HCC patients that underwent liver resection or transarterial chemoembolization were included. Pooled results showed that compared to the non-users, aspirin users of HCC had significantly reduced risk of HCC recurrence (risk ratio [RR]: 0.74, 95% confidence interval [CI]: 0.59–0.93, p = 0.01; I2 = 34%) and all-cause mortality (RR: 0.59, 95% CI: 0.47–0.73, p Conclusions Evidence from retrospective studies suggests that aspirin use is associated with reduced recurrence and all-cause mortality of HCC. These results should be validated in prospective cohort studies and randomized controlled trials.
- Published
- 2021